Company intelligence / Profile preview

Sundew

Ownership: Private
Development stage: Other

Overview

Sundew has developed biological products such as Biokos (for parasitic diseases in freshwater fish) and Ich-Away (a natural aquarium treatment), both designed to address environmental problems without harmful chemicals. Their technology is based on naturally occurring bacteria produced via fermentation to control major aquaculture pests like ich. The company claims its solutions are effective, chemical-free alternatives that improve sustainability in ocean and freshwater resources by tackling parasites, algal blooms, and invasive species.

Therapeutic areas: Infectious DiseasesOther
Modalities: Microbial therapyRNA-based delivery (for aquatic applications)Natural actives from marine organisms
Industry: Veterinary

Partnerships

University of CopenhagenNetherlands Institute of Ecology (NIOO-KNAW)

Beyond the preview

Go deeper on Sundew.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sundew.

Explore the full profile